ArticleJCO precision oncology2021
Differential Activity of PARP Inhibitors in
Article in JCO precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis.European urology · 2025Pooled it
- PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations.JCO precision oncology · 2021Pooled it
- FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Baseline PARP-1 PET imaging in patients with advanced solid tumors with DNA damage response mutations.European journal of nuclear medicine and molecular imaging · 2026Article
- Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology.International journal of molecular sciences · 2025Review
- Two Japanese patients with metastatic castration-resistant prostate cancer with somatic biallelicInternational cancer conference journal · 2025Article
- Review
- Male Breast Cancer: Epidemiology, Diagnosis, Molecular Mechanisms, Therapeutics, and Future Prospective.Oncology research · 2025Review
- Chemotherapy and Heart-Specific Mortality in Elderly Men with Prostate Cancer: A Propensity Score Matching Analysis.PloS one · 2025Article
- Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.European urology oncology · 2024Article
- DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.JCO precision oncology · 2024Article
- Rucaparib monotherapy in the heavily pre-treated metastatic castrate-resistant prostate cancer setting: practical considerations and alternate treatment approaches.Translational andrology and urology · 2024Article
- Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer.Diseases (Basel, Switzerland) · 2024Review
- Article
- Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends.Cancer management and research · 2024Review
- Review
- Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival.JAMA network open · 2023Article
- Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?Translational cancer research · 2023Article
- Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 12 institutions in 2 countries.
Funding
Abstract
Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food and Drug Administration-approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring
methodsWe conducted a multicenter retrospective analysis involving 12 sites. We collected genomic and clinical data from 123 patients with
resultsA total of 123 patients (13
conclusionPARP inhibitor efficacy is diminished in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.